Propranolol
Propranolol is a nonselective beta-adrenergic receptor blocker and an established oral therapy for infantile hemangiomas, where propranolol hydrochloride is used as first-line treatment.
Propranolol is a nonselective beta-adrenergic receptor blocker and an established oral therapy for infantile hemangiomas, where propranolol hydrochloride is used as first-line treatment. Its activity in this setting is associated with inhibition of endothelial differentiation and vascular growth. Current clinical work is evaluating treatment safety, formulation-related effects on dosing and adverse events, quantitative erythema monitoring, and combination with pulsed dye laser therapy. Experimental studies are also examining combinations with histone deacetylase inhibitors and mitochondria-targeted propranolol conjugates such as PL37.
Beyond hemangioma, propranolol is being investigated in disease biology involving adrenergic signaling, inflammation, and tissue recovery. Studies in aged traumatic brain injury patients and experimental models associate treatment with attenuated systemic inflammation, improved cognitive outcomes, and glymphatic recovery involving pathways such as STAT3/MMP2 and Aquaporin 4. Other preclinical work is assessing its potential effects in chronic-stress-associated colorectal cancer, although these applications remain investigational.
Where the papers sit
11 papers from the last 6 months study propranolol directly · updated from PubMed 1 Nov 2026
Study type 0 clinical trials · 5 observational · 1 human data · 5 preclinical
Themes 3 themes
-
Hemangioma and Brain Injury
Hemangioma work targets vasculogenesis through HDAC inhibition and mitophagy through the mitochondria-directed conjugate PL37. TBI work links propranolol to glymphatic recovery, cognitive improvement, and reduced systemic inflammation through STAT3/MMP2 signaling. These mechanisms and endpoints remain divided between two unrelated indications. The cluster therefore has no unified biological direction.
4 papers · 36.4%
-
Infantile Hemangioma Treatment
Oral propranolol treatment is moving toward optimized combinations, formulations, and objective response assessment. Pulsed dye laser is evaluated alongside propranolol for improved area reduction, color, and aesthetic outcomes. Formulation choice remains tied to treatment response and adverse events, keeping safety central. Semi-automated erythema measurement may make follow-up more reproducible.
4 papers · 36.4%
-
Drug Delivery and Colorectal Cancer
Metal-organic frameworks and gellan gum–montmorillonite coatings are being used to increase loading and sustain propranolol release while limiting burst release. Crystallinity, zeta potential, functionality, and hemolysis provide formulation benchmarks. A separate mouse study tests propranolol during chronic stress with colorectal cancer and asks whether it has antitumor activity. These delivery and cancer studies share the drug but not a single research direction.
3 papers · 27.3%
Papers
The 11 papers from the last 6 months that study propranolol directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Hemangioma and Brain Injury (4)
- Propranolol improves cognitive function and glymphatic system recovery through STAT3/MMP2 pathway after TBI. PloS one · 21 Aug 2026 PMID 42627796
- Propranolol attenuates systemic inflammatory response in aged traumatic brain injury patients. International immunopharmacology · 5 Aug 2026 PMID 42556280
- Discovery of a mitochondria-targeted propranolol conjugate PL37 that induces mitophagy for potent anti-hemangioma activity. Bioorganic & medicinal chemistry · 11 Jul 2026 PMID 42435577
- HDAC inhibition reprograms stem cell fate to suppress infantile hemangioma vasculogenesis. Angiogenesis · 4 Jun 2026 PMID 42240910
Infantile Hemangioma Treatment (4)
- Evaluation of the efficacy of oral propranolol combined with pulsed dye laser versus monotherapy with oral propranolol in the treatment of mixed infantile hemangiomas. Lasers in medical science · 10 Oct 2026 PMID 42858197
- Semi-automated erythema quantification in infantile haemangioma receiving propranolol: a pilot feasibility study. Pediatric surgery international · 22 Sept 2026 PMID 42771183
- Impact of propranolol formulation on treatment response and adverse events in infantile hemangioma: A single-center retrospective cohort study. Medicine · 18 Jul 2026 PMID 42469970
- Oral propranolol treatment safety in infantile hemangiomas. The Journal of dermatological treatment · 25 May 2026 PMID 42179355
Drug Delivery and Colorectal Cancer (3)
- Efficient Propranolol Delivery Enabled by Manganese-Based Bioactive Metal-Organic Frameworks With High Loading Capacity. ChemistryOpen · 19 Oct 2026 PMID 42894273
- Gellan gum-montmorillonite nanocomposite films as tablet coatings for sustained-release drug delivery: simultaneous burst suppression and extended release duration. International journal of biological macromolecules · 23 Jun 2026 PMID 42336014
- Investigating the efficacy of propranolol in treating chronic stress combined with colorectal cancer in mice and its antitumor potential. European journal of pharmacology · 2 Jun 2026 PMID 42229739
By study type
Observational studies and case reports (5)
- Evaluation of the efficacy of oral propranolol combined with pulsed dye laser versus monotherapy with oral propranolol in the treatment of mixed infantile hemangiomas. Lasers in medical science · 10 Oct 2026 PMID 42858197
- Semi-automated erythema quantification in infantile haemangioma receiving propranolol: a pilot feasibility study. Pediatric surgery international · 22 Sept 2026 PMID 42771183
- Propranolol attenuates systemic inflammatory response in aged traumatic brain injury patients. International immunopharmacology · 5 Aug 2026 PMID 42556280
- Impact of propranolol formulation on treatment response and adverse events in infantile hemangioma: A single-center retrospective cohort study. Medicine · 18 Jul 2026 PMID 42469970
- Oral propranolol treatment safety in infantile hemangiomas. The Journal of dermatological treatment · 25 May 2026 PMID 42179355
Human data, design not indexed (1)
- Efficient Propranolol Delivery Enabled by Manganese-Based Bioactive Metal-Organic Frameworks With High Loading Capacity. ChemistryOpen · 19 Oct 2026 PMID 42894273
Preclinical: animal, cell and lab studies (5)
- Propranolol improves cognitive function and glymphatic system recovery through STAT3/MMP2 pathway after TBI. PloS one · 21 Aug 2026 PMID 42627796
- Discovery of a mitochondria-targeted propranolol conjugate PL37 that induces mitophagy for potent anti-hemangioma activity. Bioorganic & medicinal chemistry · 11 Jul 2026 PMID 42435577
- Gellan gum-montmorillonite nanocomposite films as tablet coatings for sustained-release drug delivery: simultaneous burst suppression and extended release duration. International journal of biological macromolecules · 23 Jun 2026 PMID 42336014
- HDAC inhibition reprograms stem cell fate to suppress infantile hemangioma vasculogenesis. Angiogenesis · 4 Jun 2026 PMID 42240910
- Investigating the efficacy of propranolol in treating chronic stress combined with colorectal cancer in mice and its antitumor potential. European journal of pharmacology · 2 Jun 2026 PMID 42229739
Written from 11 PubMed abstracts, each one listed by PMID above. Published: 2026-10-16. Drafted by language models from published abstracts; not medical advice.